Accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) treated with STI-571 (Gleevec): Peripheral blood (PB) and bone marrow (BM) findings

被引：0
|
作者：
Frater, JL [1 ]
Tallman, MS [1 ]
Variakojis, D [1 ]
Boehlke, L [1 ]
Peterson, LC [1 ]
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2002年 / 82卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1006
引用
收藏
页码：241A / 241A
页数：1
相关论文
共 50 条
  • [21] ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC OR ACCELERATED PHASE
    CHAMPLIN, R
    HO, W
    ARENSON, E
    GALE, RP
    BLOOD, 1982, 60 (04) : 1038 - 1041
  • [22] ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC OR ACCELERATED PHASE
    CHAMPLIN, R
    HO, W
    WINSTON, DJ
    FEIG, S
    GALE, RP
    TRANSPLANTATION PROCEEDINGS, 1983, 15 (01) : 1401 - 1404
  • [23] Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase.
    Mauro, MJ
    Deininger, MW
    O'Dwyer, ME
    Maziarz, RT
    Walker, T
    Kurilik, G
    Druker, BJ
    BLOOD, 2002, 100 (11) : 781A - 781A
  • [24] A COMPARISON OF CYTOGENETIC AND SOUTHERN BLOT ANALYSIS OF BONE-MARROW (BM) AND PERIPHERAL-BLOOD CELLS (PB) IN PATIENTS (PTS) GRAFTED FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
    PRANGE, E
    SCHMITZ, N
    HELBIG, W
    KRAHL, R
    SUTTORP, M
    PETERSEN, B
    LOFFLER, H
    EXPERIMENTAL HEMATOLOGY, 1991, 19 (06) : 543 - 543
  • [25] BONE MARROW (BM) MICROENVIROMENT FACTORS AS EARLY MARKERS OF RESPONSE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) TREATED WITH NILOTINIB
    Quintarelli, C.
    De Angelis, B.
    Errichiello, S.
    Caruso, S.
    Esposito, N.
    Luciano, L.
    Soverini, S.
    Terragna, C.
    Cilloni, D.
    Saglio, G.
    Martinelli, G.
    Giles, F.
    Hochhaus, A.
    Pane, F.
    HAEMATOLOGICA, 2014, 99 : 66 - 67
  • [26] Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
    Errichiello, Santa
    Caruso, Simona
    Quintarelli, Concetta
    De Angelis, Biagio
    Pugliese, Novella
    Della Pepa, Roberta
    Izzo, Barbara
    Luciano, Luigia
    Soverini, Simona
    Terragna, Carolina
    Martinelli, Giovanni
    Cilloni, Daniela
    Saglio, Giuseppe
    Annunziata, Mario
    Caocci, Giovanni
    Levato, Luciano
    Usala, Emilio
    Breccia, Massimo
    Carella, Angelo Michele
    Cascavilla, Nicola
    D'Adda, Mariella
    Galimberti, Claudia
    Giles, Frank
    Hochhaus, Andreas
    Pane, Fabrizio
    BLOOD, 2015, 126 (23)
  • [27] Impact of interferon-αtherapy duration and chronic myelogenous leukemia (CML) history on Glivec ® (STI 571) response in interferon-resistant or intolerant CML patients in chronic and in accelerated phase.
    Michallet, M
    Le, QH
    Mates, M
    Berthaud, P
    Troncy, J
    Fiere, D
    Nicolini, F
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [28] Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with Imatinib (STI-571)
    Leis, JF
    Stepan, DE
    Curtin, PT
    Ford, JM
    Peng, B
    Schubach, S
    Druker, BJ
    Maziarz, RT
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 695 - 698
  • [29] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    Fischer, T
    Reifenrath, C
    Hess, GR
    Corsetti, MT
    Kreil, S
    Beck, J
    Meinhardt, P
    Beltrami, G
    Schuch, B
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    Carella, A
    Huber, C
    LEUKEMIA, 2002, 16 (07) : 1220 - 1228
  • [30] High dose imatinib (STI571, Gleevec®) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC):: Follow-up of the phase II studies.
    Talpaz, M
    Goldman, JM
    Sawyers, CL
    Hochhaus, A
    Silver, RT
    Smith, BD
    So, C
    Gathmann, I
    Druker, BJ
    BLOOD, 2003, 102 (11) : 905A - 906A
12345